Mr Stefan Milutinovic
Timau a rolau for Stefan Milutinovic
Cyhoeddiad
2023
2022
2021
- Milutinovic, S., Abe, J., Godkin, A., Stein, J. V. and Gallimore, A. 2021. The dual role of high endothelial venules in cancer progression versus immunity. Trends in Cancer 7(3), pp. 214-225. (10.1016/j.trecan.2020.10.001)
- Lauder, S. N., Milutinovic, S., Pires, A., Smart, K., Godkin, A. and Gallimore, A. 2021. Using methylcholanthrene-induced fibrosarcomas to study tumor immunology. In: Methods in Cell Biology., Vol. 163. Elsevier, pp. 59-75., (10.1016/bs.mcb.2020.09.007)
2020
Adrannau llyfrau
- Lauder, S. N., Milutinovic, S., Pires, A., Smart, K., Godkin, A. and Gallimore, A. 2021. Using methylcholanthrene-induced fibrosarcomas to study tumor immunology. In: Methods in Cell Biology., Vol. 163. Elsevier, pp. 59-75., (10.1016/bs.mcb.2020.09.007)
Erthyglau
- Milutinovic, S. and Gallimore, A. 2023. The link between T cell activation and development of functionally useful tumour-associated high endothelial venules. Discovery Immunology 2(1), article number: kyad006. (10.1093/discim/kyad006)
- Milutinovic, S. et al. 2022. Three-dimensional imaging reveals immune-driven tumor-associated high endothelial venules as a key correlate of tumor rejection following depletion of regulatory T cells. Cancer Research Communications 2(12), pp. 1641-1656. (10.1158/2767-9764.CRC-21-0123)
- Lauder, S. N. et al. 2022. Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion. British Journal of Cancer 127, pp. 1595–1602. (10.1038/s41416-022-01917-0)
- Milutinovic, S., Abe, J., Godkin, A., Stein, J. V. and Gallimore, A. 2021. The dual role of high endothelial venules in cancer progression versus immunity. Trends in Cancer 7(3), pp. 214-225. (10.1016/j.trecan.2020.10.001)
- Pires, A. et al. 2020. Immune remodelling of the extracellular matrix drives loss of cancer stem cells and tumor rejection. Cancer Immunology Research 8(12), pp. 1520 - 1531. (10.1158/2326-6066.CIR-20-0070)
- Lauder, S. N. et al. 2020. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3. Journal for ImmunoTherapy of Cancer 8(2), article number: e000693. (10.1136/jitc-2020-000693)
Gosodiad